{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:53:05Z","timestamp":1792569185805,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.chest.2020.10.081","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T02:12:20Z","timestamp":1605579140000},"page":"1256-1264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations"],"prefix":"10.1016","volume":"159","author":[{"given":"Audra J.","family":"Schwalk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahara N.","family":"Saltijeral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henriette","family":"De La Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto F.","family":"Casal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgie A.","family":"Eapen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waree","family":"Rinsurongkawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadeerat","family":"Rinsurongkawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir","family":"Elamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack A.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Heymach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horiana B.","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.chest.2020.10.081_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/13993003.00349-2018","article-title":"ERS\/EACTS statement on the management of malignant pleural effusions","volume":"52","author":"Bibby","year":"2018","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.chest.2020.10.081_bib2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1159\/000081755","article-title":"Outpatient management of malignant pleural effusions with small-bore, tunneled pleural catheters","volume":"71","author":"Musani","year":"2004","journal-title":"Respiration"},{"issue":"10","key":"10.1016\/j.chest.2020.10.081_bib3","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<1992::AID-CNCR16>3.0.CO;2-M","article-title":"A\u00a0randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions","volume":"86","author":"Putnam","year":"1999","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.chest.2020.10.081_bib4","first-page":"1110","article-title":"Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation","volume":"42","author":"Zou","year":"2014","journal-title":"J\u00a0Int Med Res"},{"issue":"2","key":"10.1016\/j.chest.2020.10.081_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2174\/1570163813666160524142846","article-title":"Can EGFR-tyrosine kinase inhibitors (TKI) alone without talc pleurodesis prevent recurrence of malignant pleural effusion (MPE) in lung adenocarcinoma","volume":"13","author":"Verma","year":"2016","journal-title":"Curr Drug Disc Technol"},{"issue":"2","key":"10.1016\/j.chest.2020.10.081_bib6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/1061186X.2016.1200590","article-title":"Sequential treatment strategy for malignant pleural effusion in non-small cell lung cancer with the activated epithelial grow factor receptor mutation","volume":"25","author":"Lin","year":"2017","journal-title":"J\u00a0Drug Target"},{"issue":"7","key":"10.1016\/j.chest.2020.10.081_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1164\/rccm.201807-1415ST","article-title":"Management of malignant pleural effusions. An official ATS\/STS\/STR Clinical Practice Guideline","volume":"198","author":"Feller-Kopman","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2020.10.081_bib8","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1378\/chest.123.4.1188","article-title":"Effect of repeated thoracenteses on fluid characteristics, cytokines, and fibrinolytic activity in malignant pleural effusion","volume":"123","author":"Chung","year":"2003","journal-title":"Chest"},{"issue":"25","key":"10.1016\/j.chest.2020.10.081_bib9","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2020.10.081_bib10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.chest.2020.10.081_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s13665-013-0041-5","article-title":"EGFR mutations in malignant pleural effusions from lung cancer","volume":"2","author":"Shamblin","year":"2013","journal-title":"Curr Respir Care Rep"},{"issue":"2","key":"10.1016\/j.chest.2020.10.081_bib12","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.21873\/anticanres.14051","article-title":"Prognosis of EGFR-mutant lung adenocarcinoma patients with malignant pleural effusion receiving first-line EGFR-TKI therapy without pleurodesis: a single-institute retrospective study","volume":"40","author":"Kashiwabara","year":"2020","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.chest.2020.10.081_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/resp.13362","article-title":"Risk factors for pleural effusion recurrence in patients with malignancy","volume":"24","author":"Grosu","year":"2019","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.chest.2020.10.081_bib14","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.chest.2017.08.026","article-title":"Quality gaps and comparative effectiveness of management strategies for recurrent malignant pleural effusions","volume":"153","author":"Ost","year":"2018","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2020.10.081_bib15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/aje\/kwp107","article-title":"Competing risk regression models for epidemiologic data","volume":"170","author":"Lau","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.chest.2020.10.081_bib16","doi-asserted-by":"crossref","first-page":"908","DOI":"10.4143\/crt.2017.378","article-title":"EGFR mutation status in lung adenocarcinoma-associated malignant pleural effusion and efficacy of EGFR tyrosine kinase inhibitors","volume":"50","author":"Yang","year":"2018","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.chest.2020.10.081_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1378\/chest.117.1.73","article-title":"Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease","volume":"117","author":"Burrows","year":"2000","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2020.10.081_bib18","first-page":"23","article-title":"Clinical response of gefitinib on malignant pleural effusions in patients with non-small cell lung cancer","volume":"4","author":"Chen","year":"2008","journal-title":"Journal of Cancer Molecules"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369220351515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369220351515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:28:44Z","timestamp":1757924924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369220351515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0012369220351515"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2020.10.081","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2020.10.081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}